DHT and
Hair Loss.

01   How DHT Destroys Hair Follicles

Dihydrotestosterone is not testosterone. It is a more potent metabolite produced when the enzyme 5-alpha-reductase (5-AR) converts testosterone. The reaction modifies testosterone's A-ring double bond, creating a molecule with 2 to 5 times greater binding affinity for the androgen receptor and approximately 10 times greater potency at activating androgen-responsive gene transcription. Only about 10% of circulating testosterone undergoes this conversion, but in genetically susceptible scalp tissue, that fraction is enough to progressively destroy follicles over years and decades.

There are two 5-AR isoforms relevant to hair loss. Type 1 (SRD5A1) predominates in skin and sebaceous glands. Type 2 (SRD5A2) concentrates in the hair follicle itself, specifically the outer root sheath, inner root sheath, and infundibulum. Critically, Type 2 expression is significantly higher in balding frontal follicles than in DHT-resistant occipital follicles. Men with a congenital Type 2 deficiency never develop androgenetic alopecia. This makes Type 2 the primary therapeutic target, though the superior efficacy of dutasteride over finasteride confirms that Type 1 also contributes meaningfully.

Once DHT is generated locally in the follicle, it binds to androgen receptors (AR) inside dermal papilla cells (DPCs), the signaling cells that control the hair growth cycle. The DHT-AR complex dimerizes and translocates to the nucleus, where it acts as a transcription factor, switching on a destructive gene expression program. This triggers the paracrine cascade that miniaturizes the follicle step by step.

02   Why Some Follicles Survive and Others Don't

One of the most important, and most misunderstood, facts about DHT and hair loss is that DHT does not uniformly attack all scalp follicles. Occipital and temporal follicles (the sides and back of the scalp) are largely resistant to DHT. This is why the classic male pattern leaves a horseshoe of intact hair even in advanced loss, and why transplanted occipital follicles retain their DHT resistance in bald recipient sites. The resistance is genetic, established during embryonic development, and permanent.

At the molecular level, DHT-resistant follicles express significantly lower levels of androgen receptor. Studies confirm approximately 1.5 times higher AR expression in frontal versus occipital scalp. Occipital follicles also show higher AR promoter methylation, epigenetically silencing receptor expression. Additionally, they contain higher concentrations of aromatase, an enzyme that converts testosterone to estradiol rather than DHT. Women's scalp aromatase is 2 to 5 times higher than men's, explaining their generally milder loss pattern even when DHT activity is similar.

Genetically, the androgen receptor gene sits on the X chromosome at Xq11-12, which is why the maternal line is the dominant inheritance pathway for male pattern baldness. A meta-analysis of 2,074 patients (Zhuo et al., 2012) found the rs6152 G allele at the AR gene carried an odds ratio of 2.68 for AGA. Large-scale genome-wide association studies have identified over 71 independently replicated susceptibility loci explaining approximately 38% of AGA risk variance. Men carrying risk alleles at both the chromosome 20p11 locus and the AR locus face a 7-fold increased risk compared to those carrying neither.

This genetic architecture has a direct clinical implication: serum DHT testing is not a reliable diagnostic tool for AGA. Normal male serum DHT ranges from 0.3 to 0.85 ng/mL, and studies show no consistent mean difference between AGA patients and controls at the serum level. The real action is local. A landmark scalp biopsy study (Dallob et al., 1994) measured 7.37 pmol/g DHT in bald scalp versus 4.20 pmol/g in hair-bearing scalp, a 75% higher local concentration, with no difference in local testosterone. It is not how much DHT you produce systemically, but how much accumulates locally in genetically sensitive follicles.

03   The DHT Destruction Pathway

Understanding the sequence of events between DHT binding and follicle miniaturization is not just academic. Each step in this cascade is a potential treatment target, and knowing which steps are addressed by which treatments is essential for choosing the right protocol.

04   Finasteride vs Dutasteride: The Clinical Evidence

Both finasteride and dutasteride are 5-alpha-reductase inhibitors that reduce DHT production, but they are not equivalent. The difference in mechanism, potency, and clinical outcomes is clinically significant.

Finasteride 1 mg/day (Health Canada-approved for AGA) selectively inhibits Type 2 5-AR with an IC50 of 11 nM, reducing serum DHT by approximately 71% and scalp DHT by approximately 64%. The pivotal Kaufman et al. (1998) trials in 1,553 men showed an increase of 107 hairs in a 5.1 cm2 target area versus placebo at year 1, rising to 138 hairs at year 2. Five-year data showed 85.7% of patients improved. Long-term treatment reduces the likelihood of further visible hair loss by approximately 93% versus placebo over five years.

Dutasteride 0.5 mg/day inhibits all three 5-AR isoforms. It is 3 times more potent than finasteride at Type 1 and over 100 times more potent at Type 1, with a half-life of 4 to 5 weeks (versus 6 to 8 hours for finasteride). At standard dosing, dutasteride reduces serum DHT by 90 to 98% compared to finasteride's 71%. It is not Health Canada-approved for AGA (only for BPH) but is widely prescribed off-label by physicians across Canada.

The most rigorous head-to-head comparison was the ARIA trial (Gubelin Harcha et al., 2014), a randomized, double-blind study of 917 men across 39 centres. Dutasteride 0.5 mg was significantly superior to finasteride 1 mg in hair count (P=0.003), hair width (P=0.004), and photographic assessment (P=0.002) at 24 weeks. Shanshanwal and Dhurat (2017) reported even more striking differences over 24 weeks: dutasteride added 23 hairs/cm2 versus finasteride's 4 hairs/cm2.

A systematic review and meta-analysis by Zhou et al. (2019) covering 576 participants in 3 RCTs found a mean difference of 28.57 total hairs favouring dutasteride (95% CI: 18.75 to 38.39, P less than 0.00001). Long-term data from South Korea (where dutasteride has been approved for AGA since 2009) shows 89.9% of patients improved after 5 years of continuous dutasteride, with 93.9% showing at least stabilization.

The safety comparison between the two drugs is often overstated. The Zhou et al. meta-analysis found no significant differences in altered libido (P=0.54), erectile dysfunction (P=0.07), or ejaculation disorders (P=0.58) between dutasteride and finasteride. The key safety consideration unique to dutasteride is its long half-life: if side effects do occur, they may persist longer after discontinuation, and men planning conception should discuss timing with their physician.

05   Dutasteride Mesotherapy: Local Effect, Minimal Exposure

The most clinically elegant approach to DHT blockade at the scalp level is dutasteride mesotherapy: the intradermal delivery of dutasteride directly into the scalp dermis at 2 to 4 mm depth. The rationale is straightforward. If the problem is local DHT accumulation at the follicle, delivering the DHT blocker locally concentrates the therapeutic effect where it is needed while substantially limiting systemic exposure and its associated side effects.

Saceda-Corralo et al. (2017, PMC5596657) demonstrated that quarterly 0.01% dutasteride injections produced no significant changes in serum testosterone, free testosterone, or DHT levels, confirming minimal systemic absorption. The largest real-world safety dataset, also by Saceda-Corralo et al. (2022, PMID 35816059), covered 541 patients across clinical practice. The finding on sexual function was decisive: zero sexual dysfunction events across all 541 patients, compared to the 4 to 7% incidence reported with oral dutasteride. Pain at injection sites, which was mild and self-limited, was the primary adverse effect, reported by 45.5% of patients.

In terms of efficacy, mesotherapy performs meaningfully but trails oral dutasteride. Herz-Ruelas et al. (2020) systematic review found oral dutasteride increased hair count by 15.92 hairs/cm2 versus intralesional dutasteride's 7.90 hairs/cm2. However, the critical distinction is that mesotherapy's safety profile makes it suitable for patients who want DHT blockade at the scalp without the systemic hormonal suppression of daily oral dosing, and for women with androgenetic alopecia for whom oral 5-ARIs are contraindicated or undesirable.

The 2025 Almeziny systematic review and meta-analysis confirmed consistent improvements in hair density and thickness with intralesional dutasteride, along with minimal adverse events and no significant systemic hormonal effects, while acknowledging the need for larger standardized trials.

For maximum effect, the Villarreal-Villarreal et al. (2025) 280-patient study found that combined oral dutasteride plus dutasteride mesotherapy plus oral minoxidil produced the best 12-month outcomes across all groups, with 66.3% achieving excellent results. Dutasteride mesotherapy appears to function most powerfully as a local amplifier of systemic DHT blockade rather than a standalone alternative to it.

06   Why DHT Blockade Alone Is Not Enough

DHT blockade is the most clinically important intervention in androgenetic alopecia. But it addresses only one dimension of the problem. Finasteride and dutasteride halt the hormonal mechanism driving miniaturization and can partially reverse it in responsive follicles. What they do not do is actively repair the follicular microenvironment that DHT has already damaged.

Even under maximal DHT suppression with oral dutasteride, the average clinical trial gain is approximately 16 hairs per cm2. The perifollicular fibrosis, the depleted growth factor signaling, the reduced vascular density around the follicle, and the dormant bulge stem cells that have been inhibited by DHT's downstream effects on Wnt signaling all persist. Removing the hormonal insult stops the damage from progressing but does not rebuild what has already been compromised.

Consider what DHT specifically does to the Wnt signaling pathway. DHT-stimulated dermal papilla cells release DKK-1, which directly inhibits Wnt/beta-catenin signaling in follicle keratinocytes and bulge stem cells. Even after DHT levels are reduced by dutasteride, the follicle's growth factor environment remains depleted. The follicle has the brake released but still lacks the fuel to restart.

07   PRP: The Complementary Mechanism

Platelet-rich plasma (PRP) therapy addresses the downstream biological deficits that DHT blockade does not. The growth factors released from platelet alpha granules directly counteract the specific molecular pathways that DHT damages.

IGF-1 directly upregulates Wnt/beta-catenin signaling in the bulge stem cells, reversing the DKK-1-mediated suppression that DHT drives. FGF-7 activates those same bulge stem cells and stimulates dermal papilla Wnt signaling. VEGF drives angiogenesis around the follicle, rebuilding the vascular density that DHT suppresses. PDGF induces and maintains the anagen growth phase while acting as a mitogen for dermal papilla cells. EGF promotes stem cell renewal and counteracts the T-cell mediated inflammation that DHT enables.

The clinical evidence for this combination is accumulating rapidly. A 2025 Bayesian network meta-analysis (Frontiers in Medicine) covering combination therapy arms found that PRP combined with other agents significantly outperformed monotherapy. Ren et al. (2024) measured outcomes in patients receiving combined PRP plus oral finasteride plus topical minoxidil, finding 78.3% showed increased hair density, from a baseline of 118.28 to 133.30 hairs per cm2 (P less than 0.001). The Villarreal-Villarreal 280-patient study demonstrated that triple combination therapy (dutasteride oral plus mesotherapy plus minoxidil) outperformed all dual and mono approaches, with 77.5% showing at least grade 2 vertex improvement at 12 months.

Clinical estimates across published combination studies suggest PRP plus 5-ARI yields approximately 30 to 40% better results than either treatment alone. The most compelling rationale is mechanistic: DHT blockade and PRP operate on entirely different biological axes. Blocking DHT removes the hormonal driver of miniaturization. PRP rebuilds the growth factor environment that DHT depleted. Together they address the full pathological picture.

08   DHT Hair Loss Treatment in Vancouver

At Monarch MD in West Vancouver, DHT-targeted hair restoration is available as a physician-supervised protocol combining dutasteride mesotherapy and PRP hair restoration, designed around the individual findings of your hair analysis. All treatment begins with a comprehensive trichoscopy assessment that maps follicle health, determines the stage and pattern of your loss, and establishes which follicles are still viable candidates for stimulation.

Dutasteride mesotherapy is performed using intradermal injection at 2 to 4 mm depth across the affected scalp, achieving therapeutic DHT-blocking concentrations locally with minimal systemic absorption. PRP is prepared using the RegenLab Swiss closed-circuit system, producing standardized, leucocyte-reduced platelet-rich plasma at the evidence-supported 4x concentration. Both treatments are administered by Dr. Eli Akbari, MD, FRCSC, a double board-certified Facial Plastic Surgeon.

A note on Canadian prescribing context: dutasteride is available in Canada as a prescription drug for BPH (brand name Avodart). Its use for hair loss is off-label but legal and widely practiced by physicians across Vancouver and greater BC. Finasteride 1 mg (Propecia or generic) is Health Canada-approved for AGA and also readily available by prescription. Neither is covered by most provincial formularies for hair loss. Dutasteride mesotherapy as a procedure is not a drug prescription but a physician-administered treatment session, similar to PRP.

09   Frequently Asked Questions